psoriasis red scaly skin disease
Conditions
Interventions
None listed
Sponsors
Dermatologie
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients must meet the following criteria: - Adults older than 18 years of age - All patients have tot have chronique plaque psoriasis (i.e. psoriasis vulgaris) - Patients must be willing to give a written informed consent - Patients must be able to adhere to the visit schedule - Applicable in fifty patients; The doctor and the patient decided that the best treatment option was photo therapy, clobetasol 17-proprionate, dithranol or anti-TNF treatment;Criteria voor vrijwilligers: - Adults older than 18 years of age - Volunteers must be willing to give written informed consent - Volunteers must be able to adhere to the visit schedule
Exclusion criteria
Exclusion criteria: Patients will be excluded from this study when any of the following criteria listed below are met: - Children or adolescents younger than 18 years of age - Patients with relevant co-morbidities - Patients with another subtype of psoriasis than psoriasis vulgaris - Patients with a history of signs of other (inflammatory) skin diseases, for example atopic dermatitis - Patients who use medication with inhibitory effects on angiogenesis (for example Thalidomide (Softanon®), Sunitinib (Sutent®), COX-2 inhibitors as NSAIDs) - Patients with co-morbidity that positively or negatively affects angiogenesis (such as microangiopathy and/or peripheral vascular disease in diabetics, smokers, etc) - Use of anti-psoriatic medication before inclusion: - Topical medication in the last 7 days - Systemic medication or photo therapy within the last 4 weeks - Patients with multiple (superficial) wounds and excoriations - Patients with contra-indications for any kind of psoriatic treatment;Exclusion criteria for Healthy volunteers: - Children or adolescents younger than 18 years of age - Volunteers with relevant co-morbidities - Volunteers with a history or signs of other (inflammatory) skin diseases, for example atopic dermatitis and psoriasis - Volunteers who use medication with inhibitory effects on angiogenesis (for example Thalidomide (Softanon®), Sunitinib (Sutent®), COX-2 inhibitors as NSAIDs) - Volunteers with co-morbidity that positively or negatively affects angiogenesis (such as micro-angiopathy and/or peripheral vascular disease in diabetics, smokers, etc) - Volunteers with multiple (superficial) wounds and excoriations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main goal of this study will be an extensive evaluation of the microvasculature and angiogenesis in different phases of psoriatic disease and in uninvolved skin of psoriatic patients. In this manner more knowledge regarding angiogenesis and its impact on psoriatic lesion development, maintenance and remission of this inflammatory skin disease is to be expected. Biopsies will be processed and tissue sections will be analyzed for the presence of angiogenesis and the extent of the MVD, using immunohistochemistry (IHC) and immunofluorescence (IF). The tissues will be stained with markers for Endothelial Cells (ECs) and markers for cell proliferation and inflammation. The tissues will be visualized using microscopy, photographed and analyzed using computer software (Image J). | — |
Secondary
| Measure | Time frame |
|---|---|
| Subsequent to this (pilot) study, the relation of angiogenesis in relation to other key processes in inflammatory skin disease (i.e. recruitment of immune cells, cytokine levels, pro- and anti-angiogenic factors and epidermal proliferation) will be analyzed. | — |
Countries
Netherlands
Outcome results
None listed